Novartis
NEWS
The sale of Xiidra to Novartis and TachoSil to Ethicon is part of Takeda’s strategy to pare down debt from its $62 billion acquisition of Shire.
On March 27, the U.S. Food and Drug Administration (FDA) approved Novartis’ Mayzent (isiponimod) for adults with relapsing types of multiple sclerosis.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.
There has been a string of news stories about how big pharma is teaming up with various artificial intelligence (AI) companies to leverage real-world data and speed drug development.
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
JOBS
IN THE PRESS